{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:38Z","timestamp":1793212118607,"version":"4.5.0"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims:<\/jats:title>\n                    <jats:p>Crohn\u2019s disease is a chronic inflammatory disorder with rising global prevalence, marked by abdominal pain, diarrhea, and fatigue. Interleukin (IL)-23 plays a pivotal role in Crohn\u2019s disease pathogenesis, making it a therapeutic target. Risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit, has shown potential in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This meta-analysis evaluates the efficacy and safety of Risankizumab in achieving clinical remission, clinical response, and endoscopic remission in patients with moderate-to-severe Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Embase, Cochrane CENTRAL, Web of Science, and ClinicalTrials.gov was performed to identify randomized controlled trials (RCTs) assessing Risankizumab in Crohn\u2019s disease. Primary outcomes were clinical remission, clinical response, and endoscopic remission, with secondary outcomes focusing on treatment-related adverse events. A random-effects model estimated odds ratios (ORs) with 95% confidence intervals. Meta-regression analyzed dose- and duration-dependent effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Four RCTs involving 1774 participants showed that Risankizumab significantly improved clinical remission (OR\u2009=\u20092.223), clinical response (OR\u2009=\u20092.483), and endoscopic remission (OR\u2009=\u20094.112). Dose-dependent improvements were observed, with treatment duration affecting clinical remission (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0158) but not clinical response or endoscopic remission. Adverse event rates were comparable between Risankizumab and placebo groups (OR\u2009=\u20090.872,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.592).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Risankizumab is effective in achieving clinical and endoscopic outcomes in moderate-to-severe Crohn\u2019s disease, demonstrating dose-dependent benefits and a favorable safety profile, supporting its use as a therapeutic option. However, the limited number of studies may affect the robustness of these findings. Further large-scale RCTs are needed to validate its long-term efficacy, safety in elderly populations, and effectiveness in biologic-na\u00efve patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis were registered with the INPLASY database under registration number INPLASY202530014. The full protocol is accessible at DOI: 10.37766\/inplasy2025.3.0014.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251338743","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:40:20Z","timestamp":1747651220000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical insights into IL-23 inhibition: risankizumab for Crohn\u2019s disease through a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-4540","authenticated-orcid":false,"given":"Po-Feng","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan"},{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chiao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Kuo","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Feng","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Chenggong Road, Neihu District, Taipei City 114202, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.07.003"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.007"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21248"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00318-7"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-03078-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01762-8"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09366-4"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583"},{"key":"e_1_3_4_12_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_4_16_2","volume-title":"Cochrane handbook for systematic reviews of interventions.","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Li T, Deeks JJ. Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane, UK, https:\/\/www.training.cochrane.org\/handbook (2024)."},{"key":"e_1_3_4_17_2","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane, UK, https:\/\/www.training.cochrane.org\/handbook (2024)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386.ch13"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_4_20_2","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Li T, Deeks JJ. Chapter 9: Analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane, UK, https:\/\/www.training.cochrane.org\/handbook (2024)."},{"key":"e_1_3_4_21_2","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks JJ","year":"2024","unstructured":"Deeks JJ, Higgins JPT, Altman DG, et al.; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. 2019; In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane, UK, https:\/\/www.training.cochrane.org\/handbook (2024)."},{"key":"e_1_3_4_22_2","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Page MJ","year":"2024","unstructured":"Page MJ, Higgins JPT, Sterne JAC. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane handbook for systematic reviews of interventions. Version 6.5 (updated August 2024). Cochrane, UK, https:\/\/www.training.cochrane.org\/handbook (2024)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12679"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2831"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab089"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020250"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18110"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221130450"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad315"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.065"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv002"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17242"},{"issue":"4","key":"e_1_3_4_35_2","first-page":"309","article-title":"The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations","volume":"65","author":"Ribaldone DG","year":"2019","unstructured":"Ribaldone DG, Pellicano R, Actis GC. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations. Minerva Gastroenterol Dietol 2019; 65(4): 309\u2013318.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3631"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad108"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001437"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa260"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1496"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12674"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14979"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08014-z"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251338743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251338743","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251338743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:16:14Z","timestamp":1767687374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251338743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":44,"alternative-id":["10.1177\/17562848251338743"],"URL":"https:\/\/doi.org\/10.1177\/17562848251338743","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"17562848251338743"}}